Evidence map›Paper›PMID 24871936›Full record

ArticleBiomacromolecules2014

Multimeric disintegrin protein polymer fusions that target tumor vasculature.

Siti M Janib, Joshua A Gustafson, Radu O Minea, Stephen D Swenson, Shuanglong Liu, Martha K Pastuszka, Lye Lin Lock, Honggang Cui, Francis S Markland, Peter S Conti and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Biomacromolecules, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. AI-validated fusion proteins for local inhibition of interleukin-17A.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  11. An amphipathic alpha-helical peptide from apolipoprotein A1 stabilizes protein polymer vesicles.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Siti M JanibDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, §Medical Technology Division, Malaysian Nuclear Agency, Bangi, 43000 Kajang Selangor, Malaysia.
Joshua A Gustafson
Radu O Minea
Stephen D Swenson
Shuanglong Liu
Martha K Pastuszka
Lye Lin Lock
Honggang Cui
Francis S Markland
Peter S Conti
Zibo Li
J Andrew MacKay
Johns Hopkins University · USUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8M
LOS ANGELES BASIN CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR031986 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2010 to 2011
$21.1M
A rapid, reversible switch for controlling intracellular traffickingR21EB012281 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACKAY, JOHN ANDREW · 2010 to 2011
$438k
NCATS NIH HHS UL1 TR000130NCI NIH HHS P30 CA014089NCRR NIH HHS UL1 RR031986NCRR NIH HHS UL1RR031986NIBIB NIH HHS R21 EB012281NIBIB NIH HHS R21EB012281NIDDK NIH HHS P30 DK048522
6 · The paper itself

Abstract

Recombinant protein therapeutics have increased in number and frequency since the introduction of human insulin, 25 years ago. Presently, proteins and peptides are commonly used in the clinic. However, the incorporation of peptides into clinically approved nanomedicines has been limited. Reasons for this include the challenges of decorating pharmaceutical-grade nanoparticles with proteins by a process that is robust, scalable, and cost-effective. As an alternative to covalent bioconjugation between a protein and nanoparticle, we report that biologically active proteins may themselves mediate the formation of small multimers through steric stabilization by large protein polymers. Unlike multistep purification and bioconjugation, this approach is completed during biosynthesis. As proof-of-principle, the disintegrin protein called vicrostatin (VCN) was fused to an elastin-like polypeptide (A192). A significant fraction of fusion proteins self-assembled into multimers with a hydrodynamic radius of 15.9 nm. The A192-VCN fusion proteins compete specifically for cell-surface integrins on human umbilical vein endothelial cells (HUVECs) and two breast cancer cell lines, MDA-MB-231 and MDA-MB-435. Confocal microscopy revealed that, unlike linear RGD-containing protein polymers, the disintegrin fusion protein undergoes rapid cellular internalization. To explore their potential clinical applications, fusion proteins were characterized using small animal positron emission tomography (microPET). Passive tumor accumulation was observed for control protein polymers; however, the tumor accumulation of A192-VCN was saturable, which is consistent with integrin-mediated binding. The fusion of a protein polymer and disintegrin results in a higher intratumoral contrast compared to free VCN or A192 alone. Given the diversity of disintegrin proteins with specificity for various cell-surface integrins, disintegrin fusions are a new source of biomaterials with potential diagnostic and therapeutic applications.

Indexed as

AnimalsBiocompatible MaterialsBreast NeoplasmsCell Line, TumorCell MembraneDisintegrinsElastinHumansHuman Umbilical Vein Endothelial CellsIntegrinsMice, NudeMicroscopy, ConfocalMicroscopy, Electron, TransmissionNanoparticlesPeptidesPolymersBiocompatible MaterialsDisintegrinsElastinIntegrinsPeptidesPolymersRecombinant Fusion Proteinsvicrostatin

Identifiers

PMID24871936
PMCPMC4098058
OpenAlexW2316467162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.